Bonnie Gillis

Articles

Switching Therapy Following Suboptimal Response in Chronic Myelogenous Leukemia

November 7th 2012

Now that several effective agents are FDA-approved for the treatment of CML, it is important to ascertain whether a treatment is working, and if not, how to respond in terms of switching treatment.

Overcoming Genetic Transformation in Multiple Myeloma

November 6th 2012

The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, which is best achieved by targeted combination therapy very early in the course of disease.

Current and Emerging Strategies for Managing Relapsed/Refractory Hodgkin Lymphoma

November 5th 2012

Transplant remains the cornerstone of treatment for relapsed/refractory Hodgkin lymphoma, but some new approaches are on the horizon and may also prove to be valid options.

One Year of Adjuvant Trastuzumab Remains Standard of Care

October 3rd 2012

Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.

Pazopanib Another Front-Line Therapy Option for Metastatic Renal Cell Carcinoma

October 2nd 2012

Pazopanib appears to be another good option for first-line therapy of metastatic renal cell carcinoma along with sunitinib.

Updated Data Show T-DM1 Improves Overall Survival in HER2-Positive Breast Cancer

October 1st 2012

An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Positive Results in ALK-Positive NSCLC With First ALK Inhibitor

October 1st 2012

Crizotinib extended PFS and improved response rates compared with single-agent chemotherapy with pemetrexed or docetaxel in patients with advanced, previously treated, ALK-positive, NSCLC.

Updated Regorafenib Survival Results Confirm Effectiveness

October 1st 2012

Patients with heavily pretreated metastatic colorectal cancer who received regorafenib experienced a sustained survival benefit across all prespecified subgroups.

BRAF Inhibitor Plus MEK Inhibitor Encouraging in Metastatic Melanoma

September 29th 2012

Combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in patients with melanoma that had BRAF V600 mutations.

Gefitinib: Small Benefit as Second-Line Therapy in Esophageal Cancer

September 29th 2012

Gefitinib improved progression-free survival and some quality of life measures when used as second-line therapy for esophageal cancer.

Carfilzomib Shows Promise as Alternative to Bortezomib in Multiple Myeloma

August 2nd 2012

Two separate clinical trials presented at ASCO 2012 suggest that carfilzomib would be a safe and effective alternative to bortezomib for the treatment of multiple myeloma, following progression.

Research Further Supports Aflibercept Benefit in Metastatic Colorectal Cancer

July 30th 2012

The phase III VELOUR trial demonstrated that the addition of aflibercept to FOLFIRI improved overall survival compared with placebo plus FOLFIRI in patients with metastatic colorectal cancer.

Studies Support Efficacy of Axitinib as First- and Second-Line Kidney Cancer Treatment

July 30th 2012

Research presented at ASCO 2012 demonstrated the efficacy of axitinib (Inlyta) as both a first- and second-line treatment in patients with metastatic renal cell carcinoma.

Lapatinib Equivalent to Trastuzumab as Neoadjuvant Therapy, but Less Effective in Metastatic Setting

July 24th 2012

Two phase III studies presented at ASCO 2012 explored the role of lapatinib in the treatment of HER2-positive breast cancer.

Insights From Genomic Approaches to Oncology Discovery

April 12th 2012

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Support for Dose Titration of Axitinib in AXIS Trial Results

April 5th 2012

The concept of dose titration in patients with mRCC who fail to achieve therapeutic levels on axitinib was validated by a secondary analysis.

EBRT More Toxic, Costly Than Radical Prostatectomy or Brachytherapy

April 2nd 2012

EBRT led to more long-term toxicity and higher treatment-related costs compared with radical prostatectomy or brachyherapy.

Trial Affirms Survival Benefit of Novel Antiandrogen Signaling Agent MDV3100 in Advanced Prostate Cancer

March 30th 2012

The investigational agent MDV3100 extended survival in men with late-stage castration-resistant prostate cancer in the phase III AFFIRM trial.

Database Analysis Finds IMRT More Effective Than CRT and Proton Beam in Prostate Cancer

March 29th 2012

IMRT was superior to CRT in reducing recurrence and significant side effects in men with localized prostate cancer, according to a comparative effectiveness study based on the SEER-Medicare database.

Lenalidomide Improves Outcomes in Asymptomatic High-Risk Smoldering and Newly Diagnosed Myeloma

March 23rd 2012

Continuous treatment with lenalidomide given early prolonged the time to progression, compared with no treatment in patients with high-risk, asymptomatic, smoldering, multiple myeloma.